Annual Review | Dr. Jun Guo: Advances in Systemic Therapy for Melanoma in 2024

Annual Review | Dr. Jun Guo: Advances in Systemic Therapy for Melanoma in 2024

Malignant melanocytes can appear in various tissues throughout the body, most commonly in the skin and mucous membranes, and are highly aggressive. With continuous advancements in targeted therapy, immunotherapy, and biological therapy, even advanced melanoma can, in many cases, be managed as a chronic disease. Looking back at 2024, what were the key research developments and treatment strategies in systemic therapy for melanoma? Oncology Frontier invited Dr. Jun Guo, Vice President of the Chinese Society of Clinical Oncology (CSCO) and professor at Peking University Cancer Hospital, to provide an expert review and summary. From Professor Guo’s annual analysis, it is evident that numerous novel treatment strategies have already begun or are poised to impact clinical practice, including some pioneering approaches originating from China.
Annual Review | Dr. Wenbin Qian：Advancements in CAR-T Cell Therapy for B-Cell Lymphoma

Annual Review | Dr. Wenbin Qian：Advancements in CAR-T Cell Therapy for B-Cell Lymphoma

In recent years, the field of hematologic malignancies has witnessed numerous groundbreaking advancements, with Chinese researchers making increasingly significant contributions, particularly in the area of cellular therapy. Their work has greatly accelerated both academic development and clinical practice in this domain. As we step into the new year, Hematology Frontier has invited Dr. Wenbin Qian from The Second Affiliated Hospital of Zhejiang University School of Medicine to provide an in-depth review of CAR-T cell therapy for B-cell lymphoma, summarizing approved CAR-T products, clinical trial data, real-world outcomes, and ongoing challenges. Additionally, this discussion explores strategies for enhancing CAR-T therapy, including novel targets, dual-target CAR-T designs, and gene-editing improvements, aiming to offer valuable insights for clinical practice and future research directions.
ASH 2024 | Dr. Neha Mehta-Shah Discusses Challenges and Innovations in T-Cell Lymphoma Treatment

ASH 2024 | Dr. Neha Mehta-Shah Discusses Challenges and Innovations in T-Cell Lymphoma Treatment

Significant progress has been made in the treatment of T-cell lymphomas in recent years. However, challenges persist in managing relapsed/refractory disease, selecting optimal therapies, and determining the best treatment sequencing for patients. To address these issues, the 2024 American Society of Hematology (ASH) Annual Meeting featured an educational session titled Addressing Unmet Needs in T-Cell Lymphomas. This session brought together leading experts to provide insights and practical guidance based on the latest research and clinical experiences. Hematology Frontier had the privilege of speaking with session chair Dr. Neha Mehta-Shah from Washington University’s Siteman Cancer Center. In this discussion, she shared her perspectives on unmet needs, treatment strategies for relapsed/refractory peripheral T-cell lymphoma (PTCL), innovative therapies, and the role of autologous and allogeneic transplants in PTCL.